18KIT
Title: (TBC)
An update on Nemaura Medical's various new
undertakings in the UK and the US with its innovative
non-invasive sensor.
Nemaura Medical is a
medical technology
company focused
on developing and
commercializing non-invasive
wearable sensors and supporting
personalized lifestyle and weight
reduction programmes. It has
announced initial results from
patient studies of its metabolic health
programme, Miboko, with the NHS.
The initial pilot program recruited
30 individuals that were classified
as obese, according to their BMI*.
The first group of 10 patients have
been enrolled in the program for
more than 12 weeks. Results indicate
that these individuals achieved an
average weight loss of 3.7lbs and
an average BMI improvement of
0.6 after 10 weeks, with 100% of
participants achieving some weight
loss. This level of average weight
loss exceeds some of the publicly
reported results in studies of other
weight loss programmes. As the
Miboko programme is optimized over
time, average weight loss is expected
to increase. The trial is designed to
continue for at least one year, with
new participants being enrolled
each month.
Feedback from participants shows
that use of the body-worn sensor
led to greater engagement and an
element of 'gamification' that is
anticipated to lead to sustained use
and encourage incremental dietary
and lifestyle changes through a
combination of personalized data
and targeted education modules.
Participants expressed their
willingness to continue with the
programme, reporting that they do
not see Miboko as a traditional diet
plan, which the company expects will
avoid diet fatigue and drop-off rates
widely associated with many weight
loss programs.
Daily wear sensor
Faz Chowdhury, Ph.D., CEO of
Nemaura Medical comments, "These
results are incredibly encouraging,
as they validate the approach that
we developed some time ago that
integrates the use of a non-invasive
glucose sensor with personalized,
app-driven coaching and analytics.
We look forward to continuing the
study with the National Health
Service and anticipate seeing
increasingly robust findings as we
continue to follow these users and
initiate new users each month."
The Miboko program is the first to
integrate a daily-wear non-invasive
glucose sensor with a lifestyle app,
which includes recording of food
and drink, educational content,
and an analytics platform. The
wellness program provides each
user a metabolic score based on
diet, exercise, and glucose response
to food intake, which is determined
by the sensor. Users are given
personalized recommendations to
help them lose weight, potentially
avoid chronic health issues, and enjoy
a better quality of life.
As studies continue, lessons
learned will be used to improve
and introduce new features into
the program. The integration of
Nemaura's daily-wear non-invasive
glucose sensor is a unique feature
that is unavailable in any other plan,
and the Company is now evaluating
options to provide the core part of
the program and glucose sensors
as add-ons to existing diet and
metabolic health programs globally.
The Company expects the UK
National Health Service will publish
detailed study results following
further analysis. See sidebar for more
info on Miboko.
In the USA
The company is currently
commercialising sugarBEAT and
proBEAT. SugarBEAT is a CE mark
approved Class IIb medical device,
as a non-invasive and flexible
continuous glucose monitor (CGM)
providing actionable insights
derived from real time glucose
measurements and daily glucose
trend data, which may help people
with diabetes and prediabetes to
better manage, reverse, and prevent
the onset of diabetes.
Nemaura has submitted a PMA